ERBB2 and lung carcinoma: The therapeutic targeting of HER2 in lung cancer has been studied for decades, and the first targeted therapy, an antibody drug conjugate (ADC) called trastuzumab deruxtecan (T-DXd), was only approved in August 2022 in patients with HER2 MUT who had previously received systemic therapy [29].